437982-68-8

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-TERT-BUTOXYCARBONYLAMINO-PHENYL)-PROPIONIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex organic molecules. 2-(4-TERT-BUTOXYCARBONYLAMINO-PHENYL)-PROPIONIC ACID's protective tert-butoxycarbonylamino group ensures that amines remain intact and unreacted during the synthesis process, allowing for the development of new drug candidates with specific therapeutic targets.
Used in Organic Chemistry Research:
In the field of organic chemistry, 2-(4-TERT-BUTOXYCARBONYLAMINO-PHENYL)-PROPIONIC ACID is utilized as a research tool to explore novel synthetic pathways and reaction mechanisms. Its unique structure provides opportunities for studying the effects of protecting groups on reaction outcomes and the development of new synthetic methodologies.
Used in Material Science:
2-(4-TERT-BUTOXYCARBONYLAMINO-PHENYL)-PROPIONIC ACID may also find applications in material science, where its chemical properties can be leveraged to create new materials with specific characteristics. 2-(4-TERT-BUTOXYCARBONYLAMINO-PHENYL)-PROPIONIC ACID's potential use in this industry could lead to advancements in areas such as polymer chemistry, where it could contribute to the development of materials with tailored properties for various applications.

Upstream product

• 19910-33-9 2-(4-nitrophenyl)propanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 59430-62-5 2-(4-aminophenyl)propionic acid 

Downstream Products

• 437982-69-9 tert-butyl 5-[(2-{4-[(tert-butoxycarbonyl)amino]phenyl}propanoyl)amino]-3-cyclopropyl-1H-pyrazole-1-carboxylate 

Relevant academic research and scientific papers

Amphiphilic pyridinium salts block TNFα/NFκB signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells

Cystic fibrosis (CF) is a common, lethal genetic disease, which is due to mutations in the CFTR gene. The CF lung expresses a profoundly proinflammatory phenotype, due to constitutive hypersecretion of IL-8 from epithelial cells lining the airways. In a systematic search for candidate drugs that might be used therapeutically to suppress IL-8 secretion from these cells, we have identified a potent and efficacious series of amphiphilic pyridinium salts. The most potent of these salts is MRS2481, an (R)-1-phenylpropionic acid ester, with an IC50 of ca. 1 μM. We have synthesized 21 analogues of MRS2481, which have proven sufficient to develop a preliminary structure-activity relationship (SAR). For optimal activity, we have found that the ester must be connected to the pyridinium derivative by an eight-carbon chain. An optical isomer of the lead compound, containing an (S)-1-phenylpropionic acid ester, has been found to be a much less active. The mechanism of action of MRS2481 appears to involve inhibition of signaling of the NFκB and AP-1 transcription factors to the IL-8 promoter. MRS2481 is a potent inhibitor of TNFα-induced phosphorylation and proteosomal destruction of IκBα. Inasmuch as IκBα is the principal inhibitor of the NFκB signaling pathway, preservation of intact IκBα would serve to keep the IL-8 promoter silent. We also find that MRS2481 blocks TNFα-activated phosphorylation of JNK, the c-JUN kinase. The IL-8 promoter is also activated by an AP-1 site, which requires a phospho-c-JUN/c-FOS dimer for activity. We therefore interpret these data to suggest that the mechanism of MRS2481 action is to inhibit both NFκB and AP-1 signaling on the IL-8 promoter. Given the medicinally promising properties of water-solubility, potency in the low μM concentration range, and high efficacy, we anticipate that MRS2481, or a further optimized derivative, may find an important place in the armamentarium of pharmaceutical strategies yet to be arrayed against the inflammatory phenotype of the CF lung.

Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents

Compounds represented by formula (I), as defined in the description, wherein R is a hydrogen atom or a methyl group and R1 is a group as defined in the specification, or a pharmaceutically acceptable salt thereof, are disclosed; the said compounds are use